Market closed

Editas Medicine/$EDIT

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Editas Medicine

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Ticker

$EDIT
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Cambridge, United States

Employees

265
Website
www.editasmedicine.com

Editas Medicine Metrics

BasicAdvanced
$94M
-
-$2.56
1.99
-

$94M

1.99

$11.58

$1.12

3.1M

3.747

3.666

12.58

21.914

-34.32%

-78.56%

1.516

0.54

0.54

-0.489

150.95%

-4.42%

36.11%

-7.43%

What the Analysts think about Editas Medicine

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Editas Medicine stock.

Editas Medicine Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Editas Medicine Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Editas Medicine News

AllArticlesVideos
Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

GlobeNewsWire·2 days ago
Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·1 week ago
Editas to reduce about 65% of its workforce over the next six months

Editas to reduce about 65% of its workforce over the next six months

Reuters·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EDIT

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Editas Medicine stock?

Editas Medicine (EDIT) has a market cap of $94M as of January 15, 2025.

What is the P/E ratio for Editas Medicine stock?

The price to earnings (P/E) ratio for Editas Medicine (EDIT) stock is 0 as of January 15, 2025.

Does Editas Medicine stock pay dividends?

No, Editas Medicine (EDIT) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Editas Medicine dividend payment date?

Editas Medicine (EDIT) stock does not pay dividends to its shareholders.

What is the beta indicator for Editas Medicine?

Editas Medicine (EDIT) has a beta rating of 1.99. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.